KZR [NASD]
Kezar Life Sciences, Inc.
Index- P/E- EPS (ttm)-1.04 Insider Own2.20% Shs Outstand60.63M Perf Week-0.54%
Market Cap318.31M Forward P/E- EPS next Y-1.21 Insider Trans6.25% Shs Float49.84M Perf Month-63.18%
Income-54.60M PEG- EPS next Q-0.29 Inst Own71.50% Short Float8.48% Perf Quarter-61.93%
Sales- P/S- EPS this Y-9.20% Inst Trans4.08% Short Ratio4.22 Perf Half Y-57.11%
Book/sh3.83 P/B1.43 EPS next Y-29.60% ROA-31.20% Target Price18.00 Perf Year-8.19%
Cash/sh4.18 P/C1.31 EPS next 5Y- ROE-34.00% 52W Range4.61 - 18.55 Perf YTD-67.17%
Dividend- P/FCF- EPS past 5Y-16.10% ROI- 52W High-70.40% Beta0.73
Dividend %- Quick Ratio35.30 Sales past 5Y- Gross Margin- 52W Low19.09% ATR0.86
Employees56 Current Ratio35.30 Sales Q/Q- Oper. Margin- RSI (14)23.37 Volatility9.79% 9.21%
OptionableYes Debt/Eq0.04 EPS Q/Q-3.90% Profit Margin- Rel Volume1.67 Prev Close5.49
ShortableYes LT Debt/Eq0.04 Earnings- Payout- Avg Volume1.00M Price5.49
Recom1.70 SMA20-36.65% SMA50-57.63% SMA200-52.29% Volume0 Change0.00%
Dec-08-21Initiated Wells Fargo Overweight $19
Jul-16-18Initiated William Blair Outperform
Jul-16-18Initiated Wells Fargo Outperform $30
Jul-16-18Initiated Jefferies Buy
May-12-22 04:01PM  
May-11-22 09:32AM  
08:59AM  
May-10-22 08:38AM  
May-05-22 04:30PM  
May-04-22 03:57PM  
05:57AM  
May-03-22 04:01PM  
Apr-15-22 04:05PM  
Apr-05-22 07:00AM  
Mar-24-22 11:03AM  
Mar-23-22 04:58PM  
Mar-18-22 12:42PM  
Mar-17-22 04:01PM  
Mar-02-22 07:00AM  
Dec-28-21 09:38AM  
Dec-21-21 09:38AM  
Dec-16-21 09:38AM  
Dec-10-21 07:00AM  
Dec-09-21 06:05PM  
Dec-08-21 09:38AM  
Nov-16-21 12:07PM  
11:38AM  
07:27AM  
06:02AM  
Nov-15-21 04:05PM  
Nov-11-21 07:00AM  
Nov-10-21 09:47AM  
Nov-09-21 04:05PM  
Nov-03-21 08:00AM  
Oct-27-21 08:00AM  
Oct-25-21 10:33AM  
Oct-15-21 02:12PM  
Oct-05-21 04:01PM  
Sep-21-21 02:34PM  
Sep-02-21 07:00AM  
Aug-23-21 07:01AM  
Aug-12-21 04:02PM  
Jul-26-21 04:52AM  
Jul-08-21 07:01AM  
Jun-08-21 07:01AM  
Jun-02-21 07:01AM  
Jun-01-21 04:01PM  
May-27-21 07:00AM  
May-26-21 04:01PM  
May-12-21 04:01PM  
May-10-21 04:01PM  
Apr-19-21 06:45AM  
Apr-10-21 08:30AM  
Feb-25-21 04:01PM  
Feb-16-21 12:53AM  
Feb-10-21 04:01PM  
Jan-07-21 04:02PM  
Dec-18-20 03:13AM  
Dec-15-20 07:52AM  
Dec-14-20 04:01PM  
10:46AM  
Nov-12-20 04:05PM  
Nov-05-20 04:01PM  
08:46AM  
Oct-23-20 07:26AM  
07:00AM  
Oct-19-20 02:25PM  
Oct-15-20 07:00AM  
Sep-18-20 07:30AM  
Sep-17-20 04:01PM  
Sep-10-20 07:00AM  
Aug-11-20 08:59AM  
08:53AM  
Aug-05-20 04:01PM  
Aug-03-20 04:01PM  
Jul-29-20 05:17PM  
Jun-23-20 09:16PM  
Jun-16-20 09:36AM  
Jun-12-20 07:01AM  
Jun-09-20 04:15PM  
11:15AM  
Jun-08-20 08:48PM  
06:00AM  
Jun-03-20 04:02PM  
May-28-20 04:01PM  
May-20-20 04:42PM  
May-11-20 10:35AM  
09:52AM  
08:35AM  
06:56AM  
May-07-20 04:01PM  
May-04-20 04:01PM  
Apr-09-20 06:08PM  
07:00AM  
Mar-24-20 11:30AM  
Mar-12-20 04:01PM  
Feb-26-20 04:01PM  
Feb-07-20 08:36AM  
Feb-04-20 05:50PM  
12:04PM  
Jan-31-20 08:13AM  
Dec-19-19 07:00AM  
Dec-16-19 07:29AM  
Dec-09-19 04:05PM  
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BERGER FRANKLIN MDirectorMar 21Buy14.7720,000295,400890,691Mar 22 05:45 PM
BERGER FRANKLIN MDirectorMar 18Buy16.7460,0001,004,400870,691Mar 22 05:45 PM
Kauffman MichaelDirectorJan 03Option Exercise5.915,00029,55068,690Jan 05 06:51 PM
Kauffman MichaelDirectorJan 03Sale16.455,00082,25063,690Jan 05 06:51 PM
Fowler John FranklinCEODec 14Option Exercise0.907,7006,930366,904Dec 15 06:05 PM
BERGER FRANKLIN MDirectorSep 22Option Exercise5.608,89649,818810,691Sep 23 04:26 PM
BERGER FRANKLIN MDirectorSep 21Option Exercise6.7717,792120,452801,795Sep 23 04:26 PM